检测IDH突变与监测靶向治疗反应的影像生物标志物
本文综述了质子磁共振波谱、扩散与灌注MRI、酰胺质子转移成像及氨基酸PET等多参数影像技术在检测IDH突变和监测IDH抑制剂疗效中的作用,重点讨论致癌代谢物D-2-羟基戊二酸(2-HG)的定量作为诊断与治疗监测的替代生物标志物,并提及先进扩散MRI模型捕捉微观结构改变及临床转化的局限与未来方向。
要点
- 多参数影像可用于无创检测IDH突变并监测IDH抑制剂疗效。
- 2-HG定量是IDH突变胶质瘤诊断与治疗监测的替代生物标志物。
- 先进扩散MRI模型可捕捉超出常规ADC的微观结构改变。
核心结论
- 先进多参数影像技术有望用于无创检测IDH突变并监测IDH抑制剂治疗反应。
- 2-HG定量可作为IDH突变胶质瘤诊断与治疗监测的替代生物标志物。
研究设计与样本
- 综述,聚焦IDH突变胶质瘤的多参数影像技术及其在检测IDH突变和监测IDH抑制剂反应中的作用。
主要发现
- 质子MR波谱、扩散与灌注MRI、酰胺质子转移成像及氨基酸PET成像可用于检测IDH突变和监测治疗反应。
- 2-HG是IDH突变胶质瘤的标志性致癌代谢物,其定量可作为诊断与治疗监测的替代生物标志物。
- 先进扩散MRI模型可捕捉超出常规表观扩散系数(ADC)的微观结构改变。
临床怎么用
- 可将多参数影像与2-HG定量用于IDH突变胶质瘤的无创诊断和IDH抑制剂疗效监测。
- 先进扩散MRI模型可作为补充手段评估超出常规ADC的微观结构改变。
局限性
- 上述影像技术在临床转化中仍存在局限,需进一步整合入前瞻性临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Isocitrate dehydrogenase (IDH) mutant gliomas represent a unique molecular subset of gliomas with distinct metabolic and microstructural characteristics. The recent approval of targeted IDH inhibitors marks a significant advancement in glioma therapy, thereby necessitating robust, quantitative methods for noninvasive assessment of treatment response. This review provides an overview of advanced multiparametric imaging techniques-including proton MR spectroscopy, diffusion and perfusion MRI, amide proton transfer imaging, and amino acid positron emission tomography imaging-and their role in detecting IDH-mutations and monitoring therapeutic response to IDH inhibitors. Special emphasis is placed on metabolic imaging of the oncometabolite D-2-hydroxyglutarate (2-HG), a hallmark signature of IDH-mutant gliomas, and how its quantification serves as a surrogate biomarker for diagnosis and treatment monitoring. We also highlight the potential of advanced diffusion MRI-based models, which capture microstructural alterations beyond conventional apparent diffusion coefficient metrics. Some limitations of these techniques in clinical translation are also considered, along with future directions to integrate them into prospective clinical trials.
引用
- Rajan A, Castro FR, de Godoy LL, et al. Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives. Neuro Oncol. 2026. PMID: 41698848. doi:10.1093/neuonc/noag028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。